Q&A With Scott Whitaker: AdvaMed's Next CEO On The Path Ahead
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed's board just selected Scott Whitaker, a top executive at the Biotechnology Innovation Organization, as the trade group's next CEO. Before he starts in the new role on April 4, he spoke with The Gray Sheet about his vision.
You may also be interested in...
Conference Collaboration Sign Of Growing AdvaMed, MDMA Partnership
While the two US-based medical device lobby groups, AdvaMed and MDMA, may have butted heads in the past, they are showing an increasing level of cooperation, most recently with plans to partner on the upcoming Medtech Conference in San Jose.
Next AdvaMed Chief Is BIO Exec Scott Whitaker
Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.
Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.